Drug firm Cipla now gets right to market and sale inhaled insulin, Afrezza in India after making an exclusive agreement with US-based MannKind Corporation on Wednesday.
A statement released from the company stated that Afrezza was the only United States Food and Drug Administraion (USFDA) approved insulin available for patients suffering from diabetes.
Responding to the development, Umang Vohra, Cipla MD and Global CEO, said, “Cipla is committed to providing access to innovative medicines and newer drug delivery systems to the patients. Afrezza, an inhaled insulin, is a cutting-edge product which will increase patient convenience.”
The innovative drug delivery system will revolutionise the diabetic care in India, he further added.
According to the deal, MannKind will be responsible for supplying Afrezza to Cipla while the later will obtain obtaining regulatory approvals to distribute Afrezza in India, including approval from the Drug Controller General of India.